CAJ | 학술논문

目的探讨基因1b型慢性丙型肝炎患者NS5A区基因变异与聚乙二醇干扰素α-2a(PEG-IFNα-2a)联合利巴韦林(RBV)抗病毒治疗疗效的关系.方法回顾性选择15例应用PEG-IFNα-2a/RBV抗病毒治疗的基因1b型慢性丙型肝炎患者,其中7例为快速应答(RVR),8例为无应答(NR),应用RT-PCR法扩增NS5A全长片段,用克隆测序方法进行核苷酸和氨基酸序列测定.结果没有发现与治疗应答相关的单个氨基酸或基序变异,RVR组和NR组在NS5A、ISDR、PKRBD和IRRDR区的氨基酸突变数目差别均无统计学意义,RVR组在V3区(aa 2356 ～ 2379)的氨基酸突变数目高于NR组(分别为5.3±0.5和3.4±0.6,P=0.03).结论 V3区的氨基酸突变数目与PEG-IFNα-2a联合RBV抗病毒疗效可能相关.
목적 탐토기인1b형만성병형간염환자NS5A구기인변이여취을이순간우소α-2a(PEG-IFNα-2a)연합리파위림(RBV)항병독치료료효적관계.방법 회고성선택15례응용PEG-IFNα-2a/RBV항병독치료적기인1b형만성병형간염환자,기중7례위쾌속응답(RVR),8례위무응답(NR),응용RT-PCR법확증NS5A전장편단,용극륭측서방법진행핵감산화안기산서렬측정.결과 몰유발현여치료응답상관적단개안기산혹기서변이,RVR조화NR조재NS5A、ISDR、PKRBD화IRRDR구적안기산돌변수목차별균무통계학의의,RVR조재V3구(aa 2356 ～ 2379)적안기산돌변수목고우NR조(분별위5.3±0.5화3.4±0.6,P=0.03).결론 V3구적안기산돌변수목여PEG-IFNα-2a연합RBV항병독료효가능상관.
Objective To investigate whether the variability in the NS5A region among patients with hepatitis C virus(HCV) genotype 1 b affect the response to pegylated interferon alpha-2a(PEG-IFNα-2a) and ribavirin(RBV) combination therapy.Methods We retrospectively analyzed 15 patients (7 with rapid virological response and 8 non-response to therapy) with chronic HCV genotype-1b infection treated with PEG-IFNα-2a plus RBV.The entire NS5A region was amplified by reverse transcription (RT)-PCR followed by cloned sequenced.Results No single amino acid and motif substitution were associated with different responses to therapy in any of the NSSA regions.No significant differences were found in the number of mutations in the full-length NS5A,ISDR,PKRBD,and IRRDR.The number of mutations in the V3 region (aa 2356-2379)was higher in patients with rapid virological response than in patients with non-response (5.3 ± 0.5 and 3.4 ± 0.6 respectively,P =0.03).Conclusion The number of amino acid mutations in the V3 region was correlated with RVR to PEG-IFNα-2a plus RBV therapy in HCV-1b patients.